Animal StudyPubMed ID: 38475122·2024

Gastrointestinal Side Effect Mechanisms: Vagal Afferent Signaling and GLP-1 Receptor Distribution

Sanger GJ, Piesse M, Bravo C, et al.

Neurogastroenterology & Motility, 2024

Key finding

Vagal afferent signaling and nodose ganglion GLP-1 receptor activation mediate nausea; selective GIP/glucagon agonism did not cause nausea, implicating GLP-1 component.

Summary

Mechanistic animal study examining the neural and receptor mechanisms underlying GLP-1-mediated nausea and gastric dysmotility with retatrutide.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT